Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy

    NEXT STORY
    Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer Patients
    PREV STORY
    Teleflex to Present at the 31st Annual Piper Jaffray Healthcare Conference
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Progenics Sends Letter to Shareholders

    author_avatar
    NASDAQ Market News

    Global Companion Diagnostics Market (2020 to 2025) – Increasing Number of Clinical Trials Presents Opportunities

    author_avatar
    NASDAQ Market News

    The Alliance for Regenerative Medicine Releases Agenda for 2018 Cell & Gene Meeting on the Mesa

    WASHINGTON, DC, Aug. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for ...

    author_avatar
    NASDAQ Market News